everolimus + calcineurin inhibitor

Everolimus + calcineurin inhibitor is a combination immunosuppressive therapy used primarily in kidney and other solid organ transplantation. Everolimus is a mammalian target of rapamycin (mTOR) inhibitor that suppresses T-cell and B-cell proliferation by inhibiting the mTOR pathway, which is critical for cell cycle progression in lymphocytes. Calcineurin inhibitors (CNIs), such as cyclosporine and tacrolimus, inhibit calcineurin phosphatase activity, thereby blocking T-cell activation and interleukin-2 production. The combination takes advantage of their complementary mechanisms: everolimus allows for a reduction in CNI dosing, which can minimize nephrotoxicity while maintaining effective immunosuppression. This strategy has shown efficacy in reducing the incidence of acute rejection, preserving renal function, and lowering the risk of infection and certain malignancies compared to full-dose CNI regimens[1][2][3][4].

Other names

everolimus plus calcineurin inhibitoreverolimus plus cyclosporineeverolimus plus tacrolimus